{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:30Z","timestamp":1790380050791,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Vice Chancellor for Research, Mashhad University of Medical Sciences, Mashhad, Iran","award":["900050"],"award-info":[{"award-number":["900050"]}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["GM061851"],"award-info":[{"award-number":["GM061851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            1,2-Distigmasterylhemisuccinoyl-\n            <jats:italic>sn<\/jats:italic>\n            -glycero-3-phosphocholine (DSHemsPC) is a new lipid in which two molecules of stigmasterol (an inexpensive plant sterol) are covalently linked via a succinic acid to glycerophosphocholine. Our previous study revealed that liposome (Lip)-intercalated amphotericin B (AMB) prepared from DSHemsPC (DSHemsPC-AMB-Lip) possesses excellent colloidal properties and\n            <jats:italic>in vitro<\/jats:italic>\n            antifungal and antileishmanial activities similar to those of the liposomal AMB preparation AmBisome. The aim of this study was to determine the biodistribution and evaluate the antileishmanial effects of DSHemsPC-AMB-Lip in\n            <jats:named-content content-type=\"genus-species\">Leishmania major<\/jats:named-content>\n            -infected BALB\/c mice. The serum profile and tissue concentrations of AMB were similar in DSHemsPC-AMB-Lip- and AmBisome-treated mice after intravenous (i.v.) injection. Multiple i.v. doses of the micellar formulation of AMB (Fungizone; 1 mg\/kg of body weight), DSHemsPC-AMB-Lip (5 mg\/kg), and AmBisome (5 mg\/kg) were used in\n            <jats:named-content content-type=\"genus-species\">L. major<\/jats:named-content>\n            -infected BALB\/c mouse models of early and established lesions. In a model of the early lesions of cutaneous leishmaniasis (CL), the results indicated that the level of footpad inflammation was significantly (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) lower in mice treated with DSHemsPC-AMB-Lip and AmBisome than mice treated with empty liposomes or 5% dextrose. The splenic and footpad parasite load was also significantly (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) lower in these groups of mice than in control mice that received 5% DW or free liposome. The\n            <jats:italic>in vivo<\/jats:italic>\n            activity of DSHemsPC-AMB-Lip was comparable to that of AmBisome, and both provided improved results compared to those achieved with Fungizone at the designated doses. The results suggest that systemic DSHemsPC-AMB-Lip administration may be useful for the treatment of leishmaniasis, and because it costs less to produce DSHemsPC-AMB-Lip than AmBisome, DSHemsPC-AMB-Lip merits further investigation.\n          <\/jats:p>","DOI":"10.1128\/aac.02525-16","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:30:28Z","timestamp":1497918628000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Biodistribution and\n            <i>In Vivo<\/i>\n            Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-\n            <i>sn<\/i>\n            -Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B"],"prefix":"10.1128","volume":"61","author":[{"given":"Maryam","family":"Iman","sequence":"first","affiliation":[{"name":"Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran"},{"name":"Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Huang","sequence":"additional","affiliation":[{"name":"Departments of Bioengineering, Therapeutic Sciences, and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Hoda","family":"Alavizadeh","sequence":"additional","affiliation":[{"name":"Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Francis C.","family":"Szoka","sequence":"additional","affiliation":[{"name":"Departments of Bioengineering, Therapeutic Sciences, and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud R.","family":"Jaafari","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2003.09.008"},{"key":"e_1_3_2_3_2","first-page":"303","article-title":"Antifungal chemotherapy: advances and perspectives","volume":"132","author":"Groll A","year":"2002","unstructured":"Groll A WalshT. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly132:303\u2013311.","journal-title":"Swiss Med Wkly"},{"key":"e_1_3_2_4_2","first-page":"191","article-title":"Treatment of Mediterranean visceral leishmaniasis","volume":"73","author":"Gradoni L","year":"1995","unstructured":"Gradoni L BrycesonADesjeuxP. 1995. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ73:191\u2013197.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_2_5_2","first-page":"67","article-title":"Development of liposomal polyene antibiotics: an historical perspective","volume":"6","author":"Ng A","year":"2002","unstructured":"Ng A WasanKLopez-BeresteinG. 2002. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci6:67\u201383.","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(01)00549-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/03639041003796648"},{"key":"e_1_3_2_8_2","first-page":"301","article-title":"Optimizing efficacy of amphotericin B through nanomodification","volume":"2","author":"Barratt G","year":"2006","unstructured":"Barratt G BretagneS. 2006. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomed2:301\u2013313.","journal-title":"Int J Nanomed"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.828-833.2002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(99)00133-8"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.suppl_B.39"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.752"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.01.044"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200900111"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.37"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0538-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023396258"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.47.2.187"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.3.421"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.31"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.8.1277"},{"key":"e_1_3_2_22_2","first-page":"1","article-title":"Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B","volume":"7","author":"Bellmann R","year":"2009","unstructured":"Bellmann R ClearyJDSterbaJ. 2009. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. Clin Adv Hematol Oncol7:1\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.01979.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00121a040"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2005.05.012"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.05.013"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh025"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/107175499266995"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/123.4.341"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja8065557"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196801182780302"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2476"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00870-07"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01319-08"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.2.170"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm077"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3024.1985.tb00098.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.05.009"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02525-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02525-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:54:04Z","timestamp":1645476844000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02525-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1128\/AAC.02525-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02525-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"2016-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02525-16"}}